iShares Biotechnology ETF
624 hedge funds and large institutions have $5.69B invested in iShares Biotechnology ETF in 2017 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 207 increasing their positions, 192 reducing their positions, and 77 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
12% less capital invested
Capital invested by funds: $6.44B → $5.69B (-$749M)
57% less call options, than puts
Call options by funds: $533M | Put options by funds: $1.25B
127.95% less ownership
Funds ownership: 186.53% → 58.57% (-128%)
Holders
624
Holding in Top 10
30
Calls
$533M
Puts
$1.25B
Top Buyers
| 1 | +$114M | |
| 2 | +$57.4M | |
| 3 | +$31.4M | |
| 4 |
Two Sigma Investments
New York
|
+$26.2M |
| 5 |
ACI
AMP Capital Investors
Sydney,
Australia
|
+$25.6M |
Top Sellers
| 1 | -$169M | |
| 2 | -$139M | |
| 3 | -$95.3M | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$81.7M |
| 5 |
JP Morgan Chase
New York
|
-$70.6M |